Dionex to purchase ESA Biosciences’ HPLC portfolio

Friday, 25 September, 2009

Dionex has entered into an asset purchase agreement with ESA Biosciences, a wholly owned subsidiary of Magellan Biosciences, to purchase ESA Biosciences’ HPLC-related products, HPLC clinical assays, laboratory services and assets.

This acquisition will add three HPLC detector families to the Dionex HPLC product portfolio:

  • Corona Family of Universal Charged Aerosol Detectors (CAD) is the ‘universal’ HPLC detector targeting pharmaceutical and biopharmaceutical development, manufacturing and QA/QC processes.
  • CoulArray and Coulochem detectors are electrochemical detectors targeting neuroscience, clinical, and metabolomics research applications.

Combined with Dionex expertise in electrochemistry detection for carbohydrates and glycobiology, this acquisition will position Dionex as the leading provider of comprehensive electrochemistry solutions for liquid chromatography.

Related News

Billion-dollar deal for UQ's molecular clamp vaccine tech

Sanofi has entered into an agreement to acquire Vicebio, a biotech company formed in 2018 to...

Director of scandal-ridden Forensic Science Queensland resigns

Dr Linzi Wilson-Wilde resigned from her position one month after being suspended by Queensland...

$492m pathology hub coming to Westmead Health Precinct

The NSW Health Pathology Statewide Hub will be delivered to Westmead Health Precinct, as part of...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd